Russell Investments Group
PLX icon

Russell Investments Group’s Protalix BioTherapeutics PLX Stock Holding History

Russell Investments Group’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.7K Buy
24,765
+12,515
+102% +$26.5K ﹤0.01% 3588
2026
Q1 		$26.6K Buy
12,250
+4,983
+69% +$12.4K ﹤0.01% 3529
2025
Q4 		$13.1K Sell
7,267
-198
-3% -$405 ﹤0.01% 3730
2025
Q3 		$16.6K Buy
+7,465
New +$12.2K ﹤0.01% 3649
2024
Q3 		– Sell
-519
Closed -$607 – 3773
2024
Q2 		$607 Buy
+519
New +$613 ﹤0.01% 3490
2023
Q4 		– Sell
-2,764
Closed -$4.59K – 3286
2023
Q3 		$4.59K Buy
+2,764
New +$4.96K ﹤0.01% 3158

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MSFS
Main Street Financial Solutions Newtown, Pennsylvania $1.56B AUM 24.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Russell Investments Group's PLX Position: Q2 2026 in Review

Russell Investments Group increased its Protalix BioTherapeutics (PLX) stake by 102% in Q2 2026, buying an estimated $26.5K and bringing the position to 24,765 shares worth $57.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3588.

Russell Investments Group first reported a position in PLX in Q3 2023 and has held it in 6 quarters since. 41 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Russell Investments Group held 24,765 shares of Protalix BioTherapeutics worth $57.7K as of Q2 2026.
  • Russell Investments Group bought 12,515 Protalix BioTherapeutics shares in Q2 2026, an estimated $26.5K.
  • Protalix BioTherapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3588 holding.
  • Russell Investments Group first reported a position in Protalix BioTherapeutics in Q3 2023 and has held it in 6 quarters since.
  • 41 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.